Remote Assessment of OCT Scans for BCC Detection

Status Not yet recruiting

Clinical Trial Summary

Basal cell carcinoma (BCC) is the most common form of cancer and entails approximately 80% of all cutaneous malignancies. This locally destructive neoplasm is commonly diagnosed by punch biopsy which is considered painful, causes procedural scarring and carries a small risk of infection and re-bleeding associated with invasive procedures. Moreover, awaiting the results of the subsequent histopathological examination causes treatment delay and can be stressful for the patient. The drawbacks of biopsy could be overcome by optical coherence tomography (OCT), a non-invasive diagnostic modality that may replace biopsy in up to 66% of patients. However, OCT assessors are scarce which hinders the implementation of OCT. This problem may be addressed by teledermatology in which remote OCT assessment by an assessor facilitates simultaneous assessment for multiple clinics. Remote OCT assessment withholds the OCT assessor from visually inspecting the lesion. But the effect of visual inspection on the diagnostic accuracy remains unknown and the question arises whether visual inspection is necessary for accurate OCT assessment. In this diagnostic case-control study we will determine whether distant OCT assessment without visual information on the lesion is non-inferior to distant OCT assessment with clinical and dermoscopic photographs (CDP-OCT).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06273709
Study type	Observational
Source	Maastricht University Medical Center
Contact	Tom Wolswijk, MD MSc
Phone	+31(0)43- 387 7295
Email	tom.wolswijk@mumc.nl
Status	Not yet recruiting
Phase
Start date	March 1, 2024
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04552990` - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT04229277` - Fast Track Diagnosis of Skin Cancer by Advanced Imaging	N/A
Completed	`NCT05608902` - Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Completed	`NCT05077033` - Intratumoral phIL12 GET	Phase 1
Active, not recruiting	`NCT04928222` - Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)	Phase 1/Phase 2
Recruiting	`NCT04929535` - Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment	Phase 2
Completed	`NCT02662244` - Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma	N/A
Completed	`NCT00959647` - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study	Phase 2
Completed	`NCT00793169` - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed	`NCT00586040` - Photochemical Tissue Bonding	Phase 2
Completed	`NCT00473343` - Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma	Phase 3
Active, not recruiting	`NCT06024629` - cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Not yet recruiting	`NCT05324202` - New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management	N/A
Withdrawn	`NCT04099446` - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A
Completed	`NCT01201915` - A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma	Phase 2
Completed	`NCT01208831` - An East Asian Study of LDE225	Phase 1
Completed	`NCT01260987` - Fractional CO2 Laser Assisted Photodynamic Therapy	Phase 2/Phase 3
Completed	`NCT01014819` - A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions	N/A
Completed	`NCT00472043` - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma	Phase 3